ClinicalTrials.gg
TerminatedNCT04678453ASK-ADUpdated Mar 1, 2024

Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)

A Phase 1 interventional study of SNK01 in Alzheimer Disease and Neuro-Degenerative Disease, sponsored by NKGen Biotech, Inc.. Terminated at 1 site in Mexico. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by NKGen Biotech, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated after completing the dose escalation portion of the study. The expansion cohort was not initiated to conduct a global trial based on the approved US IND using a new manufacturing process.

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Alzheimer Disease with a site in Mexico — 10 open to participants now, 11 under way, 8 of them phase 3. Alzheimer Disease · Mexico.

Enrollment
41st of 41
10 · median 587
Started
2021
with 4 others
Phase 1
Only one
of the 44
Registered
29th of 44
by date

Among the 44 studies in Alzheimer Disease with a site in Mexico, this one is the 41st largest by enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2021, is the only one in phase 1, and was the 29th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

10 of the 44 studies in Alzheimer Disease with a site in Mexico are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Alzheimer Disease with a site in Mexico, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent, for the treatment of subjects with Alzheimer's disease.

03

Conditions studied

  • Alzheimer Disease
  • Neuro-Degenerative Disease

Keywords

  • Natural killer cell
  • NK cell
  • Expanded natural killer cell
  • Alzheimer's Disease
  • Neurodegenerative diseases
  • Neurocognitive disorders
  • Brain diseases
  • Autologous natural killer cell
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the informed consent form and protocol. If the subject is incapable of giving or signing informed consent, the subject must have a legally authorized representative willing to consent on their behalf.
  • Subject must be ≥ 55 to 85 years old at the time of consent.
  • Magnetic resonance imaging (MRI) scans of the brain within the past six months reveal evidence and findings consistent with Alzheimer's disease, including hippocampal volume loss and/or overall cerebral atrophy (cerebral volume loss).
  • Fluorodeoxyglucose-positron emission tomography (FDG-PET) scans of the brain within the past six months reveal evidence and findings consistent with mild cognitive impairment or Alzheimer's disease.
  • Subject presenting, during evaluation by the study Investigator, to have spontaneous memory loss or presenting abnormal memory function in early screening.
  • Subject must be in good health with adequate hearing and vision.
  • Subject must have a reliable caregiver.
  • Women of who are not abstinent and intend to be sexually active with a nonsterilized male partner must be willing to use an adequate method of throughout the study and for one month following the last day of the last administration of final study drug dose. Acceptable methods include hormonal contraception (oral contraceptives [taken 90 days prior to administration of study drug], intrauterine devices (IUD), or double barrier methods (e.g., vaginal diaphragm/vaginal sponge plus condoms, or condom plus spermicidal jelly), sexual abstinence, or a vasectomized partner.

Exclusion criteria

Exclusion Criteria:

  • Any medical or neurological conditions, other than Alzheimer's disease, that could contribute to the cause of cognitive impairment in the subject. Examples include, but are not limited to, frontotemporal dementia (FTD), Lewy body dementia, vascular dementia, Parkinson's disease, corticobasal degeneration, Creutzfeldt-Jakob disease, progressive supranuclear palsy, Huntington's disease, normal pressure hydrocephalus, seizure disorders or cerebral hypoxia, post-traumatic stress disorder (PTSD), or alcohol or medication use or abuse.
  • Subject does not present with signs of mild cognitive impairment or Alzheimer's disease at screening, or during evaluation by the study Investigator.
  • Subject presents with significant brain disease including hemorrhage or infarction.
  • Subject has a history of cerebrovascular accident or (TIA), or unexplainable loss of consciousness during the past year.
  • Subject has a history of schizophrenia, schizoaffective disorder, major depressive disorder (MDD), bipolar disorder, or any other psychiatric disease.
  • Subject has a history of seizure episodes within the past three years.
  • Subject has uncontrolled diabetes mellitus.
  • Subject has a history of unstable angina, myocardial infarction, chronic heart failure, or clinically relevant conduction abnormalities within the year prior to screening.
  • Subject suffers from renal or hepatic failure.
  • Subject is infected with the (HIV), (Hep B), (Hep C), or any other infection or active systemic disease.
  • Subject is using anticoagulants (except aspirin at or below a prophylactic dose).
  • Subject is currently exceeding the normal recommended dosage for any drug used to treat Alzheimer's disease (e.g., memantine or acetylcholinesterase inhibitors [AChEI]).
  • Subject has to MRI scans, FDG-PET scans, or lumbar spinal taps.
  • Subject whose safety is considered to be at risk from trial's intervention, as determined by the study Investigator.
  • Pregnant or lactating female subjects.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Cohort 1 - Low dose SNK01

    SNK01 (low dose) administered once every three weeks (Q3W) for four cycles.

    Biological: SNK01

  • Experimental
    Cohort 2 - Medium dose SNK01

    SNK01 (medium dose) administered Q3W for four cycles.

    Biological: SNK01

  • Experimental
    Cohort 3 - High dose SNK01

    SNK01 (high dose) administered Q3W for four cycles.

    Biological: SNK01

  • Experimental
    Cohort 4 - SNK01 at Maximum Tolerated Dose (MTD) / Recommended Phase 2 Dose (RP2D)

    SNK01 (at MTD/RP2D) administered Q3W for four cycles.

    Biological: SNK01

Interventions

  • BiologicalSNK01

    Patient-specific ex vivo expanded autologous natural killer cells

06

What researchers measure

Primary outcomes

  1. To determine the safety profile of SNK01 monotherapy in patients with mild cognitive impairment (MCI) or Alzheimer's Disease by monitoring for adverse events.

    Evaluated by the number of treatment emergent adverse event (TEAE) Grade 3 or higher considered to be related to SNK01, adverse events (AEs) of Grade 3 or higher using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) v5.0, measurements of vital signs, clinical laboratory tests and physical examination.

    Time frame: Up to 6 months

  2. To determine the tolerability of SNK01 monotherapy in patients with mild cognitive impairment (MCI) or Alzheimer's Disease by monitoring for adverse events.

    Evaluated by the number of treatment emergent adverse event (TEAE) Grade 3 or higher considered to be related to SNK01, adverse events (AEs) of Grade 3 or higher using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) v5.0, measurements of vital signs, clinical laboratory tests and physical examination.

    Time frame: Up to 6 months

  3. To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of SNK01 monotherapy.

    Assessed by the incidence of dose-limiting toxicities, defined by treatment emergent adverse event (TEAE) Grade 3 or higher considered to be related to SNK01, in each dose level.

    Time frame: Up to 6 months

Secondary outcomes

  1. To assess preliminary efficacy of SNK01 measured by Alzheimer's Disease Assessment Scale Cognitive subscale (ADAS-Cog).

    Time frame: Baseline, Week 11, End of Study (Week 22)

  2. To assess preliminary efficacy of SNK01 measured by Mini-Mental Status Exam (MMSE).

    Time frame: Baseline, Week 11, End of Study (Week 22)

  3. To assess preliminary efficacy of SNK01 measured by Clinical Dementia Rating Scale: Sum of Boxes (CDR-SB).

    Time frame: Baseline, Week 11, End of Study (Week 22)

  4. To assess preliminary efficacy of SNK01 measured by Alzheimer's Disease Composite Score (ADCOMS).

    Time frame: Baseline, Week 11, End of Study (Week 22)

  5. To assess preliminary efficacy of SNK01 measured by cerebrospinal fluid (CSF) biomarkers: amyloid beta 42, T-tau and P-tau.

    Time frame: Baseline, Week 11, End of Study (Week 22)

07

Study locations

1 site
  • Hospital Angeles Tijuana
    Tijuana, Baja California 22010, Mexico
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Aug 2023, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2020
First posted
Dec 22, 2020
StartActual
Jan 6, 2021
Primary completionActual
Aug 16, 2023
CompletionActual
Jan 31, 2024
Last update
Mar 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04678453
Lead sponsor
NKGen Biotech, Inc.
Responsible party
Sponsor
First posted
Dec 22, 2020
Start date
Jan 6, 2021
Primary completion
Aug 16, 2023
Completion
Jan 31, 2024
Last update
Mar 1, 2024

Study contacts

Clemente Humberto Zúñiga Gil, MD
principal investigator · Hospital Angeles Tijuana

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Troculeucel

Start the discussion